Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients.
Jürgen HarreiterLana Kosi-TreboticAlbert LukasPeter WolfYvonne WinhoferAnton LugerAlexandra Kautzky-WillerMichael R KrebsPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2017)
Sponsored by the Medical University of Vienna and in part supported by Sanofi-Aventis.